Cargando…
Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
Ustekinumab (UST) is a human IgG1K monoclonal antibody that binds to the p40 receptor subunit bound by cytokines IL-12 and IL-23. It is indicated in both Crohn’s disease and ulcerative colitis as a second-line agent. The safety and efficacy of UST in children and young adults has not been thoroughly...
Autores principales: | Sunny, Julee, Fonseca, Ashley G., Crim, Alisa Muñiz, Goyal, Alka, Felipez, Lina M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158453/ https://www.ncbi.nlm.nih.gov/pubmed/37168900 http://dx.doi.org/10.1097/PG9.0000000000000205 |
Ejemplares similares
-
Very Early-Onset Inflammatory Bowel Disease (VEO-IBD) Presenting with Recurrent Leukocytoclastic Vasculitis Preceded by Streptococcal Pharyngitis
por: Fonseca, Ashley, et al.
Publicado: (2021) -
Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease
por: Fonseca, Ashley, et al.
Publicado: (2021) -
Letter to the Editor in Response to: Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
por: Samalik, Joann, et al.
Publicado: (2023) -
Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020) -
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)